NextDocs announced it has formed a partnership with Information Services International-Dentsu, Ltd.
NextDocs Corporation, a provider of regulated content management and compliance solutions for the life sciences industry, announced it has formed a partnership with Information Services International-Dentsu, Ltd. (ISID), an IT solutions provider in Japan, for the delivery of NextDocs document management solutions for life science companies. Under the partnership agreement, ISID will provide marketing, sales, professional services and support for NextDocs Enterprise Content Management (ECM) platform for Clinical Trials, Regulatory Document Management, and Quality Management Systems to life sciences companies in Japan. ISID will offer customers full delivery services including integration, migration and design for the NextDocs ECM platform. In addition, NextDocs and ISID will co-invest in marketing, sales, training and development including local language support to offer higher values for life science companies.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.